News
Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity: San Diego Wednesday, August 20, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback